A review intended to inform a recommendation
This review was conducted to inform an update to the American Cancer Society’s recommendations. It compares PSA-based screening strategies with no screening or other strategies. It does not, on its own, constitute a new recommendation.
The authors included 29 publications, comprising an earlier review, publications from six trials and four observational studies. Two reviewers independently assessed the risk of bias and the strength of the evidence. However, the supplied dossier contains only the PubMed abstract, not the full text.
Fewer advanced cancers, a variable effect on mortality
PSA screening was associated with more diagnoses of low-risk cancers, less advanced or metastatic disease at diagnosis and a lower cumulative incidence of metastatic disease.
For prostate cancer deaths, some trials reported a reduction, but the findings were inconsistent. According to the authors, the differences could depend in particular on screening protocols, PSA thresholds and participant characteristics. The abstract does not provide the sample sizes, follow-up durations and numerical results needed to estimate the absolute benefit.
Harms are part of the picture
The review identifies overdiagnosis, false-positive results, biopsy-related complications and harms associated with treatments following screening. The number of cancers detected therefore cannot, on its own, serve as a measure of benefit.
The abstract does not quantify how often these harms occur. It does not allow a direct comparison, for a given population, between the complications caused and the deaths or cases of metastatic disease prevented.
What this review changes—and leaves unresolved
This review supports the existence of possible benefits from PSA screening, without establishing a uniform benefit for all men or all strategies. It does not allow a choice of starting age, screening frequency or PSA threshold.
The takeaway is therefore neither “screen routinely” nor “never screen.” It is that the reduction in advanced disease must be assessed alongside the risks of screening, not separately.
Limitations to keep in mind
Only the PubMed abstract was consulted. Absolute benefits and harms, detailed participant characteristics and follow-up durations are not available in the dossier. Funding and conflicts of interest have not been verified.
What we can take away
PSA screening may reduce advanced prostate cancer, but its effect on mortality varies across trials, and its harms must be included in the assessment.
Sources and provenance
- Prostate-specific antigen-based screening for prostate cancer: A systematic review to inform an American Cancer Society guideline.
Source date: 2026-11-15.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté


